Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Satisfying International Classification of Disease-10 (ICD) diagnostic criteria of schizophrenia;~* Positive and Negative Syndrome Scale (PANSS) total score ≥ 60~Exclusion criteria:~* Refractory schizophrenia or Patients treated with sufficient clozapine for a minimum period of 6-8 weeks without improvement;~* Participation into another clinical trial within the last month;~* Patients previously or currently treated with amisulpride;~* Patients receiving clozapine within the past 1 month or treated with long-acting formulation of antipsychotic medication within the past 2 months;~* Patients receiving electric convulsive therapy or physical therapy within the past 1 month;~* Patients with coexisting severe systemic diseases;~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Amisulpride (Type: EXPERIMENTAL): Patients are treated with Amisulpride referring to the dosage and usage section in Chinese Solian® PI. Amisulpride dosage is adjusted based on individual response and reaches the sufficiency within 1 week

Based on this trial design, predict the completion outcome and termination type (if applicable).